Every 424B that Heartbeam, Inc. (BEAT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow BEAT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BEAT filings page.
HeartBeam, Inc. is launching an “at‑the‑market” equity program to sell up to $25,000,000 of common stock from time to time through Titan Partners Securities as sales agent. Titan will receive a cash commission of 3.0% of gross proceeds and may be deemed an underwriter.
The company’s common stock trades on Nasdaq under “BEAT”; the last reported price on August 13, 2026 was $0.5898 per share, implying up to about 42.4 million shares if fully utilized at that price, compared with 56,349,171 shares outstanding before this offering. Net proceeds are intended for working capital and general corporate purposes, with management retaining broad discretion over deployment.
HeartBeam is a pre‑revenue medical technology company focused on ambulatory, cable‑free, synthesized 12‑lead ECG solutions, supported by a growing international patent portfolio and recent FDA clearances. Independent auditors’ reports for 2024 and 2025 included explanatory paragraphs raising substantial doubt about the company’s ability to continue as a going concern, and the filing highlights dilution and share‑price pressure risks from this ATM program.
HeartBeam, Inc. is offering 12,500,000 shares of common stock at $0.80 per share in a firm commitment underwritten offering, with net proceeds estimated at approximately $8.9 million. The underwriter has a 30-day option to purchase up to 1,875,000 additional shares. The company will also issue underwriter warrants to purchase up to 625,000 shares at an exercise price of $0.92 (115% of the offering price). Proceeds are intended to fund commercialization of the FDA-cleared 12-lead synthesized ECG system, development of a 12-lead patch and heart attack detection efforts, AI capabilities, and general corporate purposes. Trading symbol is BEAT on the Nasdaq Capital Market and the last reported sale price shown in the supplement was $1.20 per share.
HeartBeam, Inc. is offering [●] shares of Common Stock and, in lieu of shares that would push a purchaser above a 4.99% ownership cap, pre-funded warrants exercisable for one share (exercise price $0.001). The offering is underwritten on a firm commitment basis and includes an up to 30-day, up-to-30% over-allotment option. The company holds two FDA clearances for its cable-free, synthesized 12-lead ECG system (arrhythmia assessment) and recently announced a commercial LOI with ClearCardio, enrollment in the ALIGN-ACS ER study, and a working prototype of a 12L patch. Management and auditors have expressed substantial doubt about the company’s ability to continue as a going concern.